Top Markets
#1 Black Phoenix Black Phoenix +862.28%
#2 QuantixAI QuantixAI +102.94%
#3 MetaDAO MetaDAO +24.81%
#4 Ontology Gas Ontology Gas +22.64%
#5 Bedrock Bedrock +21.40%
#6 Wrapped STX (Velar) Wrapped STX (Velar) +20.28%
#7 Siren Siren +20.01%
#8 Pons Pons +19.78%
#9 龙虾 (Lobster) 龙虾 (Lobster) +18.47%
#10 Stacks Stacks +16.85%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Immunovant, Inc. Immunovant, Inc.

Immunovant, Inc.

IMVT
Rank in Stocks #2340
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase,... Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Share Price
$43.60
Market Cap
$9.00B
Change (1 day)
0.65%
Change (1 year)
192.84%
Country
US
Trade Immunovant, Inc. (IMVT)

Category

Healthcare
Revenue for Immunovant, Inc. (IMVT)
Revenue in Aug 2026 TTM: 0
According to Immunovant, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Immunovant, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH